Pharmaceutical manufacturers of Citalopram hydrobromide

At Esteve Quimica, we are dedicated to the healthcare sector by providing support for the advancement and commercialization of products that enhance the health of patients. Established in 1966, our company remains privately owned despite being a part of ESTEVE, one of the largest pharmaceutical groups in Spain. Our current focus is on the development and production of small molecule intermediates and active ingredients for innovator companies, operating as a dedicated third-party contract business.

Jiangsu Nhwa Pharmaceutical Co., Ltd. was initially founded in 1978. In year 2008, Nhwa listed on the Shenzhen stock exchange with the stock code 002262. NHWA Pharma integrates R&D, production and sales together, as national psychiatric drugs designated unit, national high-tech enterprise, China’s top 100 pharmaceutical enterprises, national intellectual property rights demonstration unit, national "20 years 20 star" medical quality management enterprise star unit, international environmental certification (ISO14000) confirmed enterprise, the first batch of innovative enterprises in Jiangsu province, and vice President unit of China narcotic drug association.

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

VIRUPAKSHA ORGANICS LIMITED operates as a fully integrated manufacturer of Active Pharmaceutical Ingredients (API’s) and intermediates in Hyderabad, Telangana, India. The company is overseen by professionals from the pharmaceutical industry with over 25 years of expertise. The successful combination of technical knowledge, organizational capabilities, experience, and infrastructure has contributed to the company's achievements and expansion. Established in 2003, the company achieved an impressive turnover of USD 30 million in its 10th year of operation.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc. Natco family currently consists of around 4500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in Pharmaceutical R&D.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

Dr. Reddy’s Laboratories Ltd. functions as an integrated pharmaceutical firm, dedicated to supplying cost-effective and innovative medications to promote healthier lifestyles. With a focus on Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products, Dr. Reddy’s delivers a range of products and services such as APIs, customized pharmaceutical services, generics, biosimilars, and distinct formulations. The primary therapeutic areas of concentration encompass gastro-intestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s has a presence in various global markets, with significant engagements in the USA, Europe, India, Russia, and other CIS nations.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

We are one of world’s leading producers of key Active Pharmaceutical Ingredients (APIs) and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector. We endeavour to serve patients by moulding science and technology into therapies to improve health outcomes and people’s lives.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Jubilant Ingrevia Limited is an internationally integrated provider of Life Science products and Innovative Solutions, catering to Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial clients with tailored products and solutions that are pioneering, cost-efficient, and adhere to outstanding quality standards. Its range also encompasses personalized research and production for pharmaceutical and agrochemical customers on an exclusive basis. The organization provides a selection of over 125 products & pioneering solutions utilizing more than 35 essential chemistry and technology platforms across its three business segments of Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. With a team of over 2,100 employees serving more than 1,500 customers in over 50 countries worldwide, the company is motivated to bring value to millions of lives through innovations and state-of-the-art technology. For more information, please visit www.jubilantingrevia.com. Business Segments: Speciality Chemicals consists of distinct building blocks such as Pyridine and Picolines, Cyanopyridines, Piperidine, and their value-added derivatives. The company has recently ventured into Diketene Chemistry, currently producing Diketene esters & amide with several other Diketene derivatives in the pipeline. The Speciality Chemicals products are utilized in the production of a variety of Agrochemicals, Pharmaceuticals, Nutrition, Fine chemicals, Oilfield chemicals, Electronics, and Solvents. Nutrition & Health Solutions caters to Human & Animal Nutrition, Pharmaceutical & Personal Care segment/applications and comprises three businesses - Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, and Human Nutrition & Health Solutions. Chemical Intermediates manufactures a range of Chemical Intermediates including Acetyl Products and Speciality Ethanol.

We are a Pharmaceutical Company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.

Hua Hai Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company offering a comprehensive range of products and services. They specialize in the production of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, injectables, and oral solutions. Their product portfolio addresses various therapeutic areas such as cardiovascular health, anti-infectives, and central nervous system disorders. The company is committed to innovation through significant investment in research and development, aiming to discover new treatments and enhance existing ones. With state-of-the-art manufacturing facilities adhering to international quality standards, Hua Hai Pharmaceutical is dedicated to delivering high-quality and effective pharmaceutical solutions to global markets.

Aurore Life Sciences is a specialized manufacturer of active pharmaceutical ingredients (API) with a varied range of capabilities to enhance efficiency for generic pharmaceutical companies worldwide. Established in 2017 by a team with extensive expertise throughout the pharmaceutical supply chain, the company is dedicated to becoming the most favored partner for pharmaceuticals. At Aurore, we strive to innovate in the production and delivery of dependable high-quality products, earning the trust of both customers and regulatory bodies. Our focus on rapidly expanding capabilities has driven us to acquire, integrate, and extend our presence across multiple regions.

Our Mission is "To contribute broadly to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By channeling efforts into the research and development of new drugs, Sumitomo Pharma aims to realize this Mission and provide innovative and useful pharmaceuticals and healthcare solutions to people in Japan and around the world.

We are a global vertically integrated pharmaceutical company engaged in research and development, manufacture, sale and distribution of prescription and OTC pharmaceutical products, with global presence in more than 50 countries, including United States, Europe, Canada, Japan, Australia and Rest of the World. We offer a wide range of proprietary finished dosage formulation catering to different therapeutic segments, including CVS, CNS, gastro-intestinal, etc. in multiple dosage forms including: Immediate-release oral solids Modified release oral solids MUPS based products Chewable tablets Powder for oral solutions & Suspensions